Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
Company's non-sedating antihistamine Claritin (loratadine) has been granted six months of pediatric exclusivity, Schering announces Aug. 16. The patent for Claritin was set to expire in June 2002, the company says. The studies Schering submitted in its request for additional marketing exclusivity also are part of supplemental NDAs for Claritin syrup to expand the indications to include children two to five years old. Claritin was discussed as an appropriate switch candidate at an FDA public meeting in June (1"The Tan Sheet" July 3, p. 3)